Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis

Current Opinion in Infectious Diseases

Volumn 21, Issue 5, 2008, Pages 483-488

  Schriefer, Albert ^a   Wilson, Mary E ^b   Carvalho, Edgar M ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Immune response; Leishmania; Leishmaniasis; Polymorphism; Treatment

Indexed keywords

LEISHMANIA VACCINE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTOXIFYLLINE; PLACEBO; PROTOZOAL VACCINE;

CLINICAL TRIAL; DISEASE COURSE; DRUG RESPONSE; GENETIC POLYMORPHISM; HOST PARASITE INTERACTION; HUMAN; IMMUNOTHERAPY; LEISHMANIA; LEISHMANIASIS; NONHUMAN; REVIEW; ANIMAL; GENETICS; IMMUNOLOGY; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; IMMUNOTHERAPY; LEISHMANIA; LEISHMANIASIS; LEISHMANIASIS VACCINES; PROTOZOAN VACCINES;

EID: 55249093848     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32830d0ee8     Document Type: Review

References (61)

1. WHO. Leishmaniasis: burden of disease. 2007. http://www.who.int/ leishmaniasis/burden/en.
2. Nylen S, Masho K, Soderstrom K, et al. Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. Clin Exp Immunol 2003; 131:457-467.
3. Carvalho LP, Passos S, Bacellar O, et al. Differential immune regulation of activated T cell between cutaneous and mucosal leishmaniasis as a model for pathogenesis. Par Immunol 2007; 29:251-258.
4. Gaze ST, Dutra WO, Lessa M, et al. Mucosal leishmaniasis patients display an activated inflammatory T-cell phenotype associated with a nonbalanced monocyte population. Scand J Immunol 2006; 63:70-78.
5. Almeida RP, De Jesus AR, Rosa MEA, et al. Immunopathogenesis and immunotherapy in tegumentary leishmaniasis. Curr Res Immunol 2007; 1:91-126.
6. Nylen S, Maurya R, Eidsmo L, et al. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaiasis. J Exp Med 2007; 204:805-817.
7. Nylen S, Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 2007; 28:378-384.
8. Saha S, Mondal S, Ravindran R, et al. IL-10 and TGF-beta-mediated susceptibility in kala-azar and postkala-azar dermal leishmaniasis: the significance of amphoterecin B in the control of Leishmania donovani infection in India. J Immunol 2007; 179:5592-5603.
9. Salhi A, Rodrigues V Jr, Santoro F, et al. Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J Immunol 2008; 180:6139-6148.
10. Gomes-Silva A, Bittar RC, Nogueira RS, et al. Can interferon-g and inter-leukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection? Clin Exp Immunol 2007; 149:440-444.
11. O'Neal S, Guimarães LH, Machado PR, et al. Influence of helminth infections on the clinical course of and immune response to Leishmania braziliensis cutaneous leishmaniasis. J Infect Dis 2007; 195:142-148.
12. Morgado FN, Schubach A, Rosalino CMV, et al. Is the in situ inflammatory reaction an important tool to understand the cellular immune response in American tegumentary leishmaniasis? Br J Dermatol 2007; 158:50-58.
13. Ruiz JH, Becker I. CD8 cytotoxic T cells in cutaneous leishmaniasis. Par Immunol 2007; 29:671-678.
14. Faria DR, Gollob KJ, Barbosa J Jr, et al. Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun 2005; 73:7853-7859.
15. Eidsmol L, Nylen S, Khamesipour A, et al. The contribution of the Fas/Fasl apoptotic pathway in ulcer formation during leishmania major-induced cutaneous leishmaniasis. Am J Pathol 2005; 166:1099-1108.
16. Cabello PH, Lima AMVMD, Azevedo ES, Krieger H. Familial aggregation of Leishmania chagasi infection in northeastern Brazil. Am J Trop Med Hyg 1995; 52:364-365.
17. Ibrahim ME, Lambson B, Yousif AO, et al. Kala-azar in a high transmission foci: an ethnic and geographical dimension. Am J Trop Med Hyg 1999; 61:941-944.
18. Zijlstra EE, El-Hassan AM, Ismael A, Ghalib HW. Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg 1994; 51:826-836.
19. Peacock CS, Collins A, Shaw MA, et al. Genetic epidemiology of visceral leishmaniasis in northeastern Brazil. Gen Epidemiol 2001; 20:383-396.
20. Karplus TM, Jeronimo SMB, Chang H, et al. An association between the TNF locus and the clinical outcome of Leishmania chagasi infection. Infect Immun 2002; 70:6919-6925.
21. Bucheton B, Abel L, Kheir MM, et al. Genetic control of visceral leishmaniasis in a Sudanese population: candidate gene testing indicates a linkage to the NRAMP1 region. Genes Immun 2003; 4:104-109.
22. Mohamed HS, Ibrahim ME, Miller EN, et al. Genetic susceptibilty to visceral leishmaniasis in the Sudan: linkage and association with IL4 and IFNGR1. Genes Immun 2003; 4:351-355.
23. Mohamed HS, Ibrahim ME, Miller EN, et al. SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in the Sudan. Eur J Hum Genet 2004; 12:66-74.
24. Bucheton B, Abel L, El-Safi S, et al. A major susceptibility locus on chromosome 22q12 plays a critical role in the control of kala-azar. Am J Hum Genet 2003; 73:1052-1060.
25. Miller EN, Fadl M, Mohamed HS, et al. Y chromosome lineage- and village-specific genes on chromosomes 1p22 and 6q27 control visceral leishmaniasis in Sudan. PLoS Genet 2007; 3:e71; doi:10.1371/journal. pgen.0030071.
26. Mauricio IL, Stothard JR, Miles MA. The strange case of Leishmania chagasi. Parasitol Today 2000; 16:188-189.
27. Jeronimo SMB, Duggal P, Ettinger NA, et al. Genetic predisposition to self-curing infection with the protozoan leishmania chagasi: a genomewide scan. J Infect Dis 2007; 196:1261-1269.
28. Cabrera M, Shaw MA, Sharples C, et al. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 1995; 182:1259-1264.
29. Castelluci L, Menezes E, Oliveira J, et al. IL6-174 G/C promoter polymorphism influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. JID 2006; 194:519-527.
30. Berman J. Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 2003; 16:397-401.
31. Chappius F, Sundar S, Hailu A. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nature Rev Microbiol 2007; 5:S7-S16.
32. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19:111-126.
33. Sundar S, Mehta H, Suresh AV, et al. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004; 38:377-383.
34. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indial visceral leishmaniasis. N Engl J Med 2002; 347:1739-1746.
35. Hadighi R, Mohebali M, Boucher P, et al. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLOS Med 2006; 3:659-667.
36. Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis 2008; 46:223-231. Risk factors for antimony failure in CL included age, short disease duration (less than five weeks), and infection with Leishmania peruviana or L. braziliensis.
37. Arevalo J, Ramirez L, Adaui V, et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 2007; 195:1846-1851.
38. Azeredo-Coutinho RB, Mendonça SC, Callahan H, et al. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis. J Parasitol 2007; 93:688-693.
39. Samant M, Sahasrabuddhe AA, Singh N, et al. Proteophosphoglycan is differentially expressed in sodium stibogluconate-sensitive and resistant Indian clinical isolates of Leishmania donovani. Parasitology 2007; 134: 1175-1184. This study compared by FACS and western blot, and found statistically significant differences in the amounts of PPG between three isolates of L. donovani from cases of Bihar (India) that responded to sodium stibogluconate (SSB) and were in-vitro sensitive to SSB, and three isolates from cases that did not respond and were in-vitro resistant to SSB.
40. Hadighi R, Boucher P, Khamesipour A, et al. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res 2007; 101: 1319-1322. In this work intracellular amastigotes of L. tropica clinically and in-vitro resistant to Glucantime (N-methylglucamine) were crossresistant to Pentostam (stibogluconate), but sensitive to miltefosine and paromomycin.
41. Wyllie S, Vickers TJ, Fairlamb AH. Roles of trypanothione-S-transferase and tryparedoxin peroxidase in resistance to antimonials. Antimicrob Agents Chemother 2008; 52:1359-1365.
42. Hölscher C, Arendse B, Schwegmann A, et al. Impairment of alternative macrophage activation delays cutaneous leishmaniasis in nonhealing BALB/c mice. J Immunol 2006; 176:1115-1121.
43. Iniesta V, Gómez-Nieto LC, Corraliza I. The inhibition of arginase by N-hydroxy-L-arginine controls the growth of leishmania inside macrophages. J Exp Med 2001; 193:777-783.
44. Gaur U, Roberts SC, Dalvi RP, et al. An effect of parasite-encoded arginase on the outcome of murine cutaneous leishmaniasis. J Immunol 2007; 179:8446-8453. This is a very elegant work that not only unprecedently implicates the parasite's own arginase as a parasitism resilience factor, but also indicates that resistance to the host's clearance mechanisms is mediated, at least in part, through the inhibition of nitric oxide production by the host cells detectable both during in-vitro experiments, and also during in-vivo infections of BALB/c mice with L. mexicana.
45. Giudice A, Camada I, Leopoldo PTG, et al. Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in tegumentary leishmaniasis. BMC Infect Dis 2007; 7:1-12.
46. Vendrame CMV, Carvalho MDT, Rios FJO, et al. Effect of insulin-like growth factor-I on Leishmania amazonensis promastigote arginase activation and reciprocal inhibition of NOS2 pathway in macrophage in vitro. Scand J Immunol 2007; 66:287-296. This study shows that exposure of murine macrophages infected L. amazonensis to IGF-I leads to a significant increase in the expression and activities of both host and parasite arginases, and proliferation of the parasites within a 48h time course with the growth factor.
47. Miller MA, McGowan SE, Gantt KR, et al. Inducible resistance to oxidant stress in the protozoan Leishmania chagasi. J Biol Chem 2000; 275:33883-33889.
48. Acestor N, Masina S, Ives A, et al. Resistance to oxidative stress is associated with metastasis in mucocutaneous leishmaniasis. J Infect Dis 2006; 194:1160-1167.
49. Walker J, Acestor N, Gongora R, et al. Comparative protein profiling identifies elongation factor -1 beta and tryparedoxin peroxidase as factors associated with metastasis in Leishmania guyanensis. Mol Biochem Parasitol 2006; 145:254-264.
50. Dumas C, Ouellette M, Tovar J, et al. Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO J 1997; 16:2590-2598.
51. Saravia NG, Segura I, Holguin AF, et al. Epidemiologic, genetic, and clinical associations among phenotypically distinct populations of Leishmania (Viannia) in Colombia. Am J Trop Med Hyg 1998; 59:86-94.
52. Saravia NG, Weigle, Navas C, et al. Heterogeneity, geographic distribution, and pathogenicity of serodemes of Leishmania viannia in Colombia. Am J Trop Med Hyg 2002; 66:738-744.
53. Schriefer A, Schriefer ALF, Góes-Neto A, et al. Multiclonal Leishmania braziliensis population structure and its clinical implication in a region of endemic American tegumentary leishmaniasis (ATL). Infect Immun 2004; 72:508-514.
54. Das Gupta S, Ghosh DK, Majumder HK. A cloned kinetoplast DNA mini-circle fragment from a Leishmania spp. specific for postkala-azar dermal leishmaniasis strains. Parasitology 1991; 102:187-191.
55. Sreenivas G, Raju BV, Singh R, et al. DNA polymorphism assay distinguishes isolates of Leishmania donovani that cause kala-azar from those that cause postkala-azar dermal leishmaniasis in humans. J Clin Microbiol 2004; 42:1739-1741.
56. Salotra P, Duncan RC, Singh R, et al. Upregulation of surface proteins in Leishmania donovani isolated from patients of post kala-azar dermal leishmaniasis. Microbes Infect 2006; 8:637-644.
57. Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 2002; 15:593-598.
58. Sotto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 78:210-211.
59. Machado PRL, Lessa H, Lessa M, et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 2007; 44:788-793.
60. Almeida R, D'Oliveira A Jr, Machado P, et al. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous leishmaniasis. J Infect Dis 1999; 180:1735-1737.
61. Santos JB, Ribeiro de Jesus A, Machado PR, et al. Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous leishmaniasis ulcer: a randomized, double-blind, placebo-controlled study. J Infect Dis 2004; 190:1793-1796.